Literature DB >> 14754787

Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility.

Karen A Nolan1, Robert M Bilder, Herbert M Lachman, Jan Volavka.   

Abstract

OBJECTIVE: The catechol O-methyltransferase (COMT) Val158Met polymorphism has been associated with cognitive and behavioral phenotypes in schizophrenia. Whether COMT genotype is beneficial may depend on phenotype definition. The authors examined the effects of COMT genotype on a task that distinguishes imitation from reversal learning. They hypothesized that the Val and Met alleles would be associated with deficits in imitation learning and reversal learning, respectively.
METHOD: Twenty-six patients with schizophrenia and schizoaffective disorder completed a task requiring alternation between imitation and reversal rules.
RESULTS: Met homozygotes showed better acquisition of the imitation rule but greater deficit shifting from imitation to reversal. Val homozygotes had poorer imitation performance and slower reaction times.
CONCLUSIONS: The Met allele, by increasing tonic dopamine, may promote cognitive stability but limit cognitive flexibility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754787     DOI: 10.1176/appi.ajp.161.2.359

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  73 in total

1.  Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients.

Authors:  Weidong Ji; Ning Li; Kang Ju; Hong Zheng; Chuang Yang; Ping Xu; Silu Chen; Aiai Cao; Xue Chen; Lanting Guo
Journal:  Neurol Sci       Date:  2014-11-04       Impact factor: 3.307

2.  Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition.

Authors:  Claudia J P Simons; Ruud van Winkel
Journal:  Schizophr Bull       Date:  2012-04-24       Impact factor: 9.306

3.  A linkage and family-based association analysis of a potential neurocognitive endophenotype of bipolar disorder.

Authors:  Jonathan Savitz; Lize van der Merwe; Mark Solms; Rajkumar Ramesar
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 4.  A matched filter hypothesis for cognitive control.

Authors:  Evangelia G Chrysikou; Matthew J Weber; Sharon L Thompson-Schill
Journal:  Neuropsychologia       Date:  2013-11-05       Impact factor: 3.139

Review 5.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

6.  Identification of a novel haplotype of the human catechol-O-methyltransferase gene.

Authors:  Hyoung-Woo Bai; Bao Ting Zhu
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

7.  COMT but not serotonin-related genes modulates the influence of childhood abuse on anger traits.

Authors:  N Perroud; I Jaussent; S Guillaume; F Bellivier; P Baud; F Jollant; M Leboyer; C M Lewis; A Malafosse; P Courtet
Journal:  Genes Brain Behav       Date:  2009-10-23       Impact factor: 3.449

8.  COMT genotype affects prefrontal white matter pathways in children and adolescents.

Authors:  Moriah E Thomason; Robert F Dougherty; Natalie L Colich; Lee M Perry; Elena I Rykhlevskaia; Hugo M Louro; Joachim F Hallmayer; Christian E Waugh; Roland Bammer; Gary H Glover; Ian H Gotlib
Journal:  Neuroimage       Date:  2010-01-18       Impact factor: 6.556

9.  Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.

Authors:  S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott
Journal:  Neuroscience       Date:  2013-03-25       Impact factor: 3.590

Review 10.  Genes, cognition and brain through a COMT lens.

Authors:  D Dickinson; B Elvevåg
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.